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Background: There is scant data regarding disease presentation and treatment response among black men living
in Africa. In this study we evaluate disease presentation and early clinical outcomes among Ghanaian men with
prostate cancer treated with external beam radiotherapy (EBRT).
Methods: A total of 379 men with prostate cancer were referred to the National Center for Radiotherapy, Ghana
from 2003 to 2009. Data were collected regarding patient-and tumor-related factors such as age, prostate specific
antigen (PSA), Gleason score (GS), clinical stage (T), and use of androgen deprivation therapy (ADT). For patients
who received EBRT, freedom from biochemical failure (FFbF) was evaluated using the Kaplan-Meier method.
Results: Of 379 patients referred for treatment 69.6% had initial PSA (iPSA) > 20 ng/ml, and median iPSA was
39.0 ng/ml. A total of 128 men, representing 33.8% of the overall cohort, were diagnosed with metastatic disease at
time of referral. Among patients with at least 2 years of follow-up after EBRT treatment (n=52; median follow-up
time: 38.9 months), 3- and 5-year actuarial FFbF was 73.8% and 65.1% respectively. There was significant association
between higher iPSA and GS (8–10 vs. ≤7, p < 0.001), and T stage (T3/4 vs. T1/2, p < 0.001).
Conclusions: This is the largest series reporting on outcomes after prostate cancer treatment in West Africa. That
one-third of patients presented with metastatic disease suggests potential need for earlier detection to permit
curative-intent therapy. Data from this study will aid in the strategic development of prostate cancer research
roadmap in Ghana.
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Prostate cancer is currently the second most often diag-
nosed cancer and the sixth leading cause of cancer mor-
tality among males worldwide [1]. Incidence rates vary
widely among different regions with the highest inci-
dences noted among men from the United States and
Europe likely due to utilization of the prostate-specific
antigen (PSA) test as a screening tool. Mortality on the
other hand is highest among prostate cancer patients of
African descent. Based on recent estimates, there is a
three-fold higher mortality rate for prostate cancer* Correspondence: jkosjc@gmail.com
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reproduction in any medium, provided the oramong patients in African countries as compared to
patients in the United States and Europe [2,3]. This
trend has been partly attributed to socio-economic fac-
tors and inadequate access to healthcare [4,5], as well as
differences in genetic susceptibility [6-8].
The available medical literature for prostate cancer is
primarily from Europe and the United States. Although the
literature does emphasize the outcomes of males of African
descent, the subjects included are those who live in de-
veloped countries [9-14], which does not represent fully
the disease characteristics observed in men who reside in
African nations [15,16]. Therefore, there is a need to con-
duct further studies to better understand and describe
prostate cancer in Africa focusing on disease presentation
and biochemical failure after currently available treatments,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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improving treatment delivery and outcomes in Africa.
Reports on cancer patterns among Ghanaian men re-
ferred to the Korle Bu Teaching Hospital (KBTH) revealed
that prostate cancer comprised 64% of all genitourinary
cancers during 1980–1990 [17]. A 10-year retrospective
analysis of all cancer deaths at KBTH during 1991–2000,
reported by Wiredu and Armah, demonstrated that pros-
tate cancer was the second leading cause of cancer-related
mortality among their male patients [18]. Recently, Yarney
et al. examined the clinicopathologic features of pros-
tate cancer patients referred to KBTH during 2003–2007,
and showed that the majority of 170 patients referred
for radiotherapy at KBTH presented with initial PSA
>20 ng/ml (73%), Gleason score >7 (56%) and were symp-
tomatic at disease presentation (76%) [19]. This patient
profile differs substantially from those encountered in the
United States where median initial PSA at diagnosis is
estimated at 6.1 ng/ml and 6.3 ng/ml in Caucasians and
Black men respectively [20,21].
Clearly, Ghanaian men present with prostate cancer
that is more advanced than observed routinely in the
United States, and the cancer treatment resources differ
dramatically. Our research team plans to develop treat-
ment regimens tailored to the needs of Ghanaian men,
which may differ from guidelines currently utilized in
the Unites States and Europe in order to better address
the disease burden and improve mortality rates in
Ghana. In this study we examine early results for defini-
tive radiation therapy for prostate cancer at KBTH, and
develop a research roadmap for improving radiation
therapy delivery and outcomes in Ghanaian men.
Methods
Patient selection
With Institutional Review Board approval from KBTH
and Thomas Jefferson University, patient and treatment
data were collected retrospectively from the charts of all
patients referred to the National Center for Radiotherapy
and Nuclear Medicine at KBTH for prostate cancer treat-
ment from January 2003 to December 2009, representing
a total of 379 patients. These patients comprise the cohort
for evaluation of patient- and tumor-related factors pre-
sented in the current report (overall cohort). Among these
patients, a total of 251 patients (organ-confined cohort)
had non-metastatic disease and were, thus, considered
eligible to receive treatment with curative intent consisting
of external beam radiotherapy (EBRT) (Cobalt-60 unit),
brachytherapy, and/or androgen deprivation therapy
(ADT). A subset of this group, the Freedom From bio-
chemical Failure (FFbF) analysis cohort, was identified for
evaluation of outcomes after EBRT, with or without ADT
(52 patients). Patients who received radical prostatectomy
were not included in this analysis, since follow up datawere not available. Patients who received radical prosta-
tectomy prior to EBRT or were treated with brachytherapy
were excluded from the FFbF analysis cohort, as were
patients with radiologic or pathologic evidence of meta-
static disease prior to treatment. Inclusion criteria included
a biopsy-proven diagnosis of prostate adenocarcinoma, a
minimum of 2 years of follow up data, and at least 2 of the
following available: clinical T stage, Gleason score, or initial
PSA. All patients were initially evaluated by a thorough
history, physical examination (including digital rectal exa-
mination) followed by routine laboratory studies, bone
scan, and serial serum prostate-specific antigen (PSA) dur-
ing and after treatment. All patients were staged according
to the 1992 American Joint Committee on Cancer staging
system [22]. Patients were further stratified into low, inter-
mediate and high risk groups according to the recent
NCCN guidelines [23].
Treatment details
External beam radiotherapy
Until 2008, prostate EBRT was performed with 2-dimen-
sional treatment planning using a conventional fluoro-
scopic simulator. A 4-field box technique was applied,
with parallel-opposed pairs of antero-posterior and lat-
eral fields, to deliver up to 68- 70 Gy in 34/35 fractions
over 7 weeks. The superior border was placed at the
lower sacroiliac joint, with the inferior border 1 cm
above the bottom of the ischial tuberosities. The anterior
border on the lateral film split the pubic symphysis, and
posterior border split the S2/S3 vertebrae.
Following the acquisition of a three-dimensional (3D)
treatment planning system in 2008, prostate EBRT involves
computed tomography (CT) planning. CT scan images
were obtained in the supine position with 2.5 mm slice
cuts and transmitted to a Prowess Panther Treatment
Planning System, version 4.6 (Prowess, Inc., Concord,
California). A 3D conformal radiotherapy technique was
used. Clinical target volumes (CTV) included the prostate,
with or without seminal vesicles. For low risk patients, the
CTV included the prostate only, whereas the CTV in inter-
mediate risk patients included the prostate and the inferior
1 cm of the seminal vesicles. The entire seminal vesicles
were included in the CTV for high risk disease. Typical
margins used to generate a planning target volume (PTV)
by expanding the CTV were 1 cm, except posteriorly
where the margin was 0.6 cm.
A range of 54-60 Gy was delivered to the initial CTV
followed by a second phase, delivering an additional
10 to 14 Gy to the prostate only. Patients received a cu-
mulative central tumour dose of 68 to 74 Gy in 34 to 37
daily fractions over 7 to 7-1/2 weeks. A minimum PTV
coverage of 95% coverage was required, with dose
inhomogeneity of less than 10% and maximum point
dose was not to exceed 107% of prescription dose. Dose-
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tient, with a constraint of V60<40% and or V40<60% for
the rectum. Appropriate shielding with customised
blocks was employed to decrease the dose to the rectum
and femoral heads. Radiotherapy was delivered using a
Cobalt-60 teletherapy (GWGP 80, National Power Insti-
tute of China). Portal imaging was obtained from Cobalt
60 machine prior to and midway through treatment
course with correction of any set up errors identified.
Brachytherapy seed implantation
All patients were seeded using the real-time transrectal
ultrasound-guided technique [24]. Iodine-125 sources
(Bard Medical Division, Covington, GA, USA) were used
in all patients: low risk patients and intermediate risk
patients with PSA < 15 ng/ml were prescribed to receive
dose 160 Gy (pre-TG-43 formalism), intermediate risk
patients with PSA > 15 ng/ml and patients with high risk
disease received a partial implant of 110 Gy to the pros-
tate followed by EBRT of 45 Gy to the pelvis.
Androgen depravation therapy
ADT consisted of orchiectomy or a gonadotropin-releas-
ing hormone agonist (goserelin acetate) with or without
non-steroidal anti-androgen (flutamide or bicalutamide).
The use of ADT was dependent on the risk category of
the patient. Short term ADT was offered to intermediate
risk patients (given only concurrently during the 7–8 weeks
of radiotherapy). High risk patients received long term
ADT, given for a total of 24 months, beginning 3 months
before initiation of radiation [25]. Patients presenting with
PSA > 100 ng/ml who completed a negative metastatic
work up including bone scintigraphy and CT or magnetic
resonance imaging (MRI) of the pelvis were treated as
having localized, high-risk disease with EBRT + long term
ADT. However, those individuals with PSA > 100 ng/mL
and symptoms of new onset bone pain were treated with
ADT alone as using EBRT was deemed an exercise in futil-
ity due to high likelihood of metastatic disease.
KBTH occasionally receives referrals for consideration
of prostate EBRT for patients with rising PSA levels who
previously received orchiectomy for localized disease,
and who were not assessed at initial diagnosis for radical
prostatectomy or radiation therapy. These individuals
are evaluated with bone scintigraphy and CT or MRI of
the pelvis to determine whether regional or distant
spread of prostate cancer is present. Those without
clinical or radiological evidence of metastases are then
considered for EBRT with curative intent.
Follow-up and treatment endpoints
All patients in the FFbF analysis cohort, but not the
overall cohort, had a follow up of at least two years.
Patients were seen in follow up every three months fortwo years, then every six months for the next three years
and once a year subsequently. At each follow up visit,
evaluation included DRE and serial PSA values were
determined and recorded. When data were available,
biochemical failure in the analysis cohort was defined
according to the Phoenix definition (PSA nadir + 2 ng/mL).
Time to biochemical failure was defined from the end of
EBRT. Freedom From biochemical Failure (FFbF) was used
as an endpoint in this analysis, since it serves as a surrogate
for disease-free survival [26]. Patients with follow up data
of less than 24 months after end of EBRT were excluded
from FFbF analysis to reduce the influence of long-term
ADT on the observed values in the high-risk patients.
Statistical analysis
Frequency counts and descriptive statistics were used to
present information regarding clinical and pathological
features of the cohort. Associations between initial PSA
level and other factors, including Gleason score, clinical
T stage and patient age, were tested using Wilcoxon-
Mann–Whitney tests due to the highly skew distribution
of PSA levels. For the FFbF Analysis cohort, 3- and 5-year
FFbF rates were evaluated using the Kaplan-Meier me-
thod. Comparisons of FFbF were performed using the
log-rank statistic. The threshold for statistical significance
was defined a p-value of <0.05 for all tests. Analyses were
performed using the SAS 9.2 statistical software package
(SAS Institute Inc., Cary, NC).
Results
Patient and disease characteristics
The distribution of the clinical characteristics and treat-
ment modalities for the overall cohort (n=379), the
organ-confined cohort (n=251), and the FFbF analysis
cohort (n=52) groups are presented in Tables 1 and 2.
The median age at diagnosis among Ghanaian men was
65 years. Of all patients referred to KBTH for treatment,
69.6% had initial PSA > 20 ng/mL with a median initial
PSA of 39.0 ng/mL. As shown in Table 3, there was a
significant association between higher iPSA level and
advanced Gleason score (8–10 vs. ≤7, p < 0.001) and
clinical T stage (T3/4 vs. T1/2, p < 0.001). There was no
significant association between initial PSA and age at
presentation (<65 vs. 65+) (p= 0.099). A total of 128
men, representing 33.8% of the overall cohort, were
diagnosed with metastatic disease at time of referral and
were excluded from further analysis.
Treatment characteristics (Organ-confined cohort)
Among 251 patients with organ-confined disease, eli-
gible for definitive radiation therapy (RT), 135 patients
(53.8%) received EBRT without brachytherapy at the
KBTH (Table 2). Reasons recognized by KBTH clinicians
for patients declining EBRT included: the prohibitive
Table 1 Age and tumor characteristics for prostate cancer
patients referred for radiation therapy at Korle Bu
teaching hospital during 2003-2009
Characteristic Overall cohort
(n=379)
Organ-confined
cohort (n=251)
FFbF analysis
cohort (n=52)
n (%) n (%) n (%)
Age, Y
<60 78 (20.6) 55 (21.9) 10 (19.2)
60-64 89 (23.5) 66 (26.3) 13 (25.0)
65-69 95 (25.1) 69 (27.5) 17 (32.7)
70-74 76 (20.1) 46 (18.3) 9 (17.3)
>74 41 (10.8) 15 (6.0) 3 (5.8)
iPSA ng/ml
0-10.0 50 (13.2) 46 (18.3) 9 (17.3)
10.1-20.0 50 (13.2) 47 (18.7) 10 (19.2)
20.1-50.0 79 (20.8) 61 (24.3) 16 (30.8)
50.1-100.0 70 (18.5) 45 (17.9) 11 (21.2)
100.1-1000.0 73 (19.3) 40 (15.9) 5 (9.6)
>1000 7 (1.9) 2 (0.8) 1 (1.9)
Unknown 50 (13.2) 10 (4.0) --
Gleason
Score
≤6 130 (34.3) 114 (45.4) 25 (48.1)
7 102 (26.9) 81 (32.3) 20 (38.5)
8 to 10 71 (18.7) 40 (15.9) 5 (9.6)
Unknown 76 (20.1) 16 (6.4) 2 (3.9)
Clinical T
stage
T1 17 (4.5) 17 (6.8) --
T2 114 (30.1) 114 (45.4) 22 (42.3)
≥T3 77 (20.3) 77 (30.7) 29 (55.8)
Tx 43 (11.4) 43 (17.1) 1 (1.9)
M 128 (33.8) -- --
Risk Group
Low -- 20 (8.0) 4 (7.7)
Intermediate -- 48 (19.1) 9 (17.3)
High -- 166 (66.1) 39 (75.0)
Unknown -- 17 (6.8) --
Table 2 Treatments administered for patients referred for
radiation therapy, according to cohort
Treatment Overall cohort
(n=379)
Organ-confined
cohort (n=251)
FFbF analysis
cohort (n=52)
n (%) n (%) n (%)
EBRT 147 (38.8) 141 (56.2) 52 (100.0)
EBRT alone 20 (5.3) 18 (7.2) 4 (7.7)
EBRT + ADT 121 (31.9) 117 (46.6) 48 (92.3)
EBRT +
Brachytherapy
2 (0.5) 2 (0.8) --
EBRT+ADT+
Brachytherapy
4 (1.1) 4 (1.6) --
ADT alone 139 (36.7) 60 (23.9) --
LHRH agonist 120 (31.7) 58 (23.1) --
Orchiectomy 38 (10.0) 9 (3.6) --
Brachytherapy
alone
13 (3.4) 13 (5.2) --
Table 3 Summary of initial PSA (iPSA) levels by various
patient characteristics in the overall cohort (n = 379)
Patient
characteristic
iPSA ng/ml (quartiles) p-value
25th-percentile Median 75th-percentile
Age, Y 0.099
<65 13.3 32.9 100.0
≥65 19.9 44.8 100.0
Gleason Score < 0.001
≤7 13.9 27.9 72.8
8 to 10 34.6 68.3 268.2
Clinical T stage < 0.001
T1 - T2 9.4 19.8 39.0
T3 - T4 22.7 50.4 90.1
Yamoah et al. BMC Cancer 2013, 13:23 Page 4 of 8
http://www.biomedcentral.com/1471-2407/13/23cost of treatment, fear of radiation, and a state of denial
based on their perception of disease originating solely
from spiritual causes rather than biologic processes.
Patients treated with EBRT received a median dose of
70 Gy, delivered in 2 Gy daily fractions. Among the
organ-confined cohort, 16 patients received orchiectomy,
including 7 patients who also received EBRT. At least 214
patients (85%) with organ-confined disease presented with
intermediate-to-high risk disease (Table 1). Six patients
with low risk prostate cancer were started on ADT by
their referring urologist prior to evaluation at KBTH.Seventeen patients in the intermediate- and high-risk
groups did not receive ADT during EBRT, due to Gleason
score of 5 or less (8 patients) or unaffordable out-of-
pocket costs and other socioeconomic factors (9 patients).Treatment response (FFbF Analysis cohort)
All members of the FFbF analysis cohort (n=52) received
EBRT +/− ADT and had at least 2 years of follow up data
after treatment (Table 1). Median ADT time was
24 months. Median follow up time in this group was
38.9 months. The 3- and 5-year actuarial FFbF was 73.8%
and 65.1% respectively (Figure 1). The 5-year FFbF rates
for patients with PSA < 30 ng/mL and PSA > 30 ng/mL
were 67.0% and 63.2%, respectively (log-rank, p= 0.586).
Acute toxicity during treatment included increased
fatigue, urinary frequency, nocturia and bowel frequency,
but the rates of these events could not be assessed in the
available records. None of the patients on treatment were
0.0
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0.4
0.6
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0 1 2 3 4 5
Time since End of RT (in years)
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Figure 1 Kaplan-Meier plot of survival curve of Freedom-From
Biochemical Failure (FFbF) for the Analysis Cohort (n=52) of
patients who received external beam radiation therapy at Korle
Bu Teaching Hospital in Ghana and who were followed for at
least 2 years after treatment. Dotted lines represent 95%
confidence interval.
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hospitalization from treatment related causes.
Discussion
Over the last few decades, there has been a noted increase
in the burden of chronic diseases, especially cancer, in
Africa [27]. Simultaneously, trends in other factors such
as extensive urbanization and lifestyle changes, including
smoking, alcohol consumption, and the adaptation of a
Western diet, have been linked to an increased risk of
cancer [28]. Prostate cancer contributes significantly to
these patterns. A recent report on the cancer mortality
pattern in Ghana following a 10-year review of autopsies
and hospital mortality revealed that prostate cancer was
the second leading cause of death from cancer among
men in Ghana [18]. Furthermore, the incidence of prostate
cancer is on the rise in Ghana, due in part to the fact that
the life expectancy of working men has increase over the
last decade and better health care facilities have improved
detection of disease [19].
The current study describes characteristics of prostate
cancer patients referred to KBTH in Ghana and provides
insight into early clinical outcomes for the treatment of
advanced disease in this population. These data are
significant, in terms of defining priorities for cancer care
in West Africa, since the majority of the prostate cancer
literature originates from the United States and Western
Europe and there is an increasing awareness that results
obtained from one ethnicity may not necessarily apply to
individuals from a different ethnic origin. Over the last
two decades, data have emerged from hospital-based
cancer registries in a few African countries that provide
valuable information. Data from several articles onprostate cancer from 1981 to 2005 indicate an increased
prostate cancer risk and mortality among Nigerian men
[29-31]. Another study among Senegalese men with
prostate cancer revealed worse tumor stage and median
PSA when compared with that of African American men
[20]. Data from the current study suggest similar find-
ings in our cohort of Ghanaian men. Although this study
was done in the largest cancer center in Ghana genera-
lizing this data to all Ghanaian men with prostate cancer
must be done with caution. In this section, we will apply
these data toward consideration of research priorities
aimed at improving prostate cancer diagnosis and treat-
ment in Ghana.
PSA screening
In our study population of Ghanaian men with prostate
cancer, >90% of patients with available data presented with
intermediate- or high-risk disease, >95% with clinically T2
or greater disease, and 70% with PSA > 20 ng/ml. In
contrast, in the US population, 40-60% of prostate cancer
patients present with clinically inapparent disease, mostly
diagnosed as T1c upon trans-rectal ultrasound guided
(TRUS) biopsy [32,33]. Furthermore, less than 15% of
prostate cancer patients in the US population present with
PSA > 20 ng/ml [34]. This may be attributed to PSA
screening efforts and more frequent TRUS biopsies of
prostate in developed countries. Currently, routine yearly
PSA screening is a source of controversy in the United
States [35], but this approach is not feasible in Ghana
where the costs would be prohibitive. Moreover, the effect
of PSA screening on prostate cancer mortality in the
United States and Europe has been inconclusive. Data from
the Prostate Lung Colorectal and Ovarian (PLCO) trial did
not show a survival benefit from screening, however the
European Randomized Study of Prostate Cancer (ERSPC)
trial demonstrated a 31% reduction in the risk of death
from prostate cancer in men that had PSA screening [36].
There are major concerns that PSA screening leads to
over-diagnosis and overtreatment of indolent prostate
cancer in men which if left untreated would have little
or no impact on life expectancy [37]. However, in men
of African descent who may demonstrate more aggres-
sive disease, the lack of screening could result in an
increased number of patients presenting with high risk
disease, which would adversely impact prostate cancer
mortality rates. This is exemplified in the analysis of our
patient cohort showing a strong correlation between
PSA levels at diagnosis and advanced clinical T stage as
well as Gleason score. Based on trends of prostate can-
cer mortality in Ghana and the vast majority of patients
presenting with high risk disease, it would be advanta-
geous to develop a healthcare policy that will allow for
PSA screening along with DRE in a selected cohort of
men. Although annual PSA screening would likely exceed
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consider a program that includes less frequent screening.
Determining the appropriate initial age for screening and
the appropriate time interval for PSA screening in Ghana
is beyond the scope of this study, but future studies should
address these considerations.
Challenges to treatment delivery
Out of 251 patients eligible for definitive radiation treat-
ment with curative intent only 141 patients (56.2%)
actually received EBRT. A number of factors acting as
barriers to treatment delivery include the use of alterna-
tive medicines and traditional healing methods coupled
with inadequate health education, which often delays
correct diagnosis and initiation of treatment. Further-
more, taboos, stigmas, and false beliefs that cancer is a
“curse” often lead to delayed diagnosis and non-adherence
to treatment. Other barriers specific to radiation treatment
delivery among Ghanaian men included fear of radiation,
inflated perception of the cost of treatment, difficulty with
access to transportation to and from daily treatments, and
loss of income due to absence or inability to work.
Ghana has a population of 24 million serviced by only
two megavoltage machines in two radiation treatment
centers 250 kilometers (180 miles) apart. The lack of
accessibility to treatment centers as well as time loss and
costs incurred by patient transportation presents a huge
barrier for compliance to daily treatments. Furthermore,
the national health insurance re-imbursements payment
rate to the health care facilities is very low, which in turn
renders the out of pocket cost per treatment course per
patient enormously expensive for the average working-
class Ghanaian man. Currently, shorter course (“hypo-
fractionated”) treatment schedules are being explored
for prostate cancer, in an effort to improve patient con-
venience, reduce costs, and to take advantage of unique
radiobiological characteristics of prostate cancer that
make large fractions potentially more effective [38]. The
adaptation of a hypofractionated schedule for treatment
in Ghana would offer a profound advantage in not only
decreasing healthcare delivery costs but also improve
access to treatment by reducing transportation time and
expense for patients during radiation therapy. This
represents a potential for implementing tailored prostate
cancer treatment schemes for developing countries, an
important focus for future studies. To this end, we
propose to develop and conduct clinical trials of shorter
course radiation therapy schedules tailored to the needs
of Ghanaian prostate cancer patients.
Treatment outcomes
To date, the data presented in this article provides the
only source of published information on outcomes for
prostate cancer treatment in the West African region.Our results showed that the 3- and 5-year FFbF for
Ghanaian men with mostly intermediate to high risk
prostate cancer receiving EBRT +/− ADT was 73.8% and
65.1% respectively. In light of differences in patient
disease characteristics at diagnosis and older treatment
techniques one must consider whether to evaluate these
outcomes with respect to the latest published data using
dose escalation as reported by Zietman et al. [21] that
demonstrated a 80-90% biochemical control as opposed
to older experiences from randomized trials such as
RTOG 9202 [39] and EORTC 22863 [40] showing bio-
chemical failure rates as high as 50-76% for patients with
advanced tumors. A major drawback to this retrospect-
ive study is the limited ability to assess important end
points such as impact of treatment on cause-specific
survival and distant metastases free survival due to a
median follow up data of only 3 years. Nevertheless,
there is valuable information presented in this article
that will aid in the strategic development of a roadmap
for prostate cancer research in Ghana, with a focus on
improving therapeutic approach as well as fostering a
prudent allocation of scarce resources.
Future research needs
Results presented in this study have demonstrated that
the majority of Ghanaian men diagnosed with prostate
cancer present with very advanced stage disease. Current
treatment recommendations for advanced stage prostate
disease are based on clinical trials that include conven-
tionally-fractionated radiation therapy and long-term
ADT [39-41]. However, the availability of modern treat-
ment technologies and the more recent interest in hypo-
fractionation for prostate cancer offer an opportunity to
develop studies aimed at improving the treatment and
outcomes for Ghanaian patients with advanced stage
prostate disease. The Ghanaian prostate cancer patient
population is in need of clinical trials that seek to de-
velop novel, shorter course treatment regimens for
locally-advanced prostate cancer. We have established
collaboration between two institutions with the hope of
improving prostate cancer treatment in Ghana and plan
to develop clinical trials that can be conducted in tandem
between our two institutions. Our group encourages
approaching the design of clinical trials in a way that
includes perspective of the public health burden of pros-
tate cancer in Ghana and the specific barriers to care. We
hope to achieve progress by involving stakeholders in a
coordinated fashion to develop tailored radiation treat-
ment techniques that are cost-effective and well-suited for
the needs of Ghanaian men.
Conclusion
We have described presentation and early clinical out-
comes for a cohort of patients who received prostate
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results, our group has proposed a plan for future re-
search aimed at identifying an appropriate role for PSA
screening in this population, developing radiation ther-
apy treatment schedules that better fulfill the needs of
Ghanaian prostate cancer patients, and contributing to
understanding genetic factors associated with prostate
cancer risk and treatment response.
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